| Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer (NCT00899132) | Case Comprehensive Cancer Center | 2007-02-01 |
| Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer (NCT00429858) | Andrew Ko | 2007-01-22 |
| Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer (NCT00478010) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2007-01-19 |
| Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint (NCT00613730) | Amgen | 2007-01-01 |
| Study of Respiratory Gated Proton Beam Radiotherapy for Inoperable Pancreas Carcinoma (NCT00658801) | National Cancer Center, Korea | 2007-01-01 |
| Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery (NCT00524069) | Roswell Park Cancer Institute | 2007-01-01 |
| An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer (NCT06129812) | Seoul National University Hospital | 2007-01-01 |
| RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer (NCT00409292) | Dana-Farber Cancer Institute | 2007-01-01 |
| Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer (NCT00470535) | Roswell Park Cancer Institute | 2007-01-01 |
| Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer (NCT00897832) | Vanderbilt-Ingram Cancer Center | 2007-01-01 |
| A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma (NCT00411762) | Yale University | 2006-12-01 |
| Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00541021) | Institut Paoli-Calmettes | 2006-12-01 |
| Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer (NCT00177853) | University of Pittsburgh | 2006-12-01 |
| Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer (NCT00436410) | National Institutes of Health Clinical Center (CC) | 2006-12-01 |
| Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer (NCT00417976) | Tony Bekaii-Saab | 2006-12-01 |
| Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer (NCT00557492) | Amer Zureikat | 2006-12-01 |
| Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer (NCT00564720) | Hellenic Oncology Research Group | 2006-12-01 |
| Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer (NCT00402025) | BioVex Limited | 2006-11-01 |
| Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer (NCT00426127) | University of Iowa | 2006-11-01 |
| Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma (NCT00415454) | Henry Ford Health System | 2006-11-01 |
| Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer (NCT00622622) | Wakayama Medical University | 2006-11-01 |
| Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma (NCT00587132) | Mayo Clinic | 2006-11-01 |
| Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors (NCT00433602) | European Organisation for Research and Treatment of Cancer - EORTC | 2006-11-01 |
| Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery (NCT00436267) | Goshen Health System | 2006-11-01 |
| Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx (NCT00767273) | Stanford University | 2006-10-01 |
| Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer (NCT00769652) | Rutgers, The State University of New Jersey | 2006-10-01 |
| Abdominal Exploration Without Incisions (NCT00427752) | Jeffrey Hazey | 2006-10-01 |
| Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene (NCT00386399) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2006-10-01 |
| Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer (NCT00389610) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2006-09-11 |
| Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer (NCT00375310) | Indiana University | 2006-09-01 |
| INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer (NCT00322712) | University of New Mexico | 2006-09-01 |
| Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00425360) | Royal Liverpool University Hospital | 2006-09-01 |
| A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer (NCT00882310) | Columbia University | 2006-09-01 |
| 131-I-TM-601 Study in Adults With Solid Tumors (NCT00379132) | TransMolecular | 2006-08-01 |
| AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy (NCT00372944) | AstraZeneca | 2006-08-01 |
| Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients (NCT00383760) | National Cancer Institute (NCI) | 2006-08-01 |
| Dynamic PET acquisition-a Quantitative Technique for Grading of Malignant Tumors and Prediction of Response to Treatment (NCT00294840) | Rambam Health Care Campus | 2006-08-01 |
| A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer (NCT02694536) | Hoffmann-La Roche | 2006-08-01 |
| Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer (NCT00366457) | Massachusetts General Hospital | 2006-08-01 |
| Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery (NCT00410774) | University of California, San Francisco | 2006-07-01 |
| EUS-CPN: A Retrospective Review (NCT00577564) | Indiana University | 2006-07-01 |
| Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients (NCT01094561) | Elizabeth Hecht | 2006-07-01 |
| A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors (NCT00379639) | Celgene | 2006-07-01 |
| Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma (NCT00681798) | Sanofi | 2006-07-01 |
| Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine (NCT00440167) | PD Dr. med. Volker Heinemann | 2006-06-01 |
| Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer (NCT00593866) | University of Michigan Rogel Cancer Center | 2006-06-01 |
| A Trial of Chemo & Radiation Therapy for Pancreatic Cancer (NCT00424827) | University of Massachusetts, Worcester | 2006-06-01 |
| Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma (NCT00658840) | National Cancer Center, Korea | 2006-06-01 |
| A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer (NCT00336700) | Herbert J. Zeh, III MD, FACS | 2006-06-01 |
| 32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer (NCT00346281) | pSiMedica Limited | 2006-06-01 |
| Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer (NCT00425841) | Technical University of Munich | 2006-05-01 |
| Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00448838) | University of Miami | 2006-05-01 |
| Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer (NCT00307723) | Massachusetts General Hospital | 2006-05-01 |
| A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer (NCT00325494) | Morphotek | 2006-05-01 |
| TMS for the Treatment of Pancreatic Cancer Pain (NCT00324428) | Beth Israel Deaconess Medical Center | 2006-05-01 |
| AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00265876) | NCIC Clinical Trials Group | 2006-04-26 |
| Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer (NCT01268384) | Asan Medical Center | 2006-04-01 |
| Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer (NCT00350142) | Albert Koong | 2006-04-01 |
| ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA) (NCT00313560) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2006-03-16 |
| Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer (NCT00967291) | IRCCS San Raffaele | 2006-03-01 |
| Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer (NCT00387348) | Massachusetts General Hospital | 2006-03-01 |
| Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy (NCT01913275) | All India Institute of Medical Sciences | 2006-03-01 |
| Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine (NCT00365144) | University of California, San Francisco | 2006-02-01 |
| Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors (NCT00369109) | Barbara Ann Karmanos Cancer Institute | 2006-02-01 |
| A Phase I Study of ECO-4601 in Patients With Advanced Cancer (NCT00338026) | Thallion Pharmaceuticals | 2006-02-01 |
| Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking (NCT00365508) | Fox Chase Cancer Center | 2006-02-01 |
| Changes in Muscle Tissue in Patients With Pancreatic Cancer (NCT00369460) | Case Comprehensive Cancer Center | 2006-01-01 |
| Bupropion in Helping Adults Stop Smoking (NCT00534001) | Roswell Park Cancer Institute | 2006-01-01 |
| Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction (NCT00280709) | University Hospital, Linkoeping | 2006-01-01 |
| Clinical Outcomes in Hereditary Cancer (NCT00580021) | Memorial Sloan Kettering Cancer Center | 2006-01-01 |
| Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00408564) | Medical University of South Carolina | 2006-01-01 |
| Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer (NCT00648102) | Celldex Therapeutics | 2006-01-01 |
| Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer (NCT00305760) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2005-12-01 |
| Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer (NCT00320749) | Tony Bekaii-Saab | 2005-12-01 |
| Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene (NCT00303927) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2005-12-01 |
| Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer (NCT00243854) | Indiana University | 2005-11-01 |
| Standardization of Surgery on the Pancreatic Cancer (NCT00679913) | Seoul National University Hospital | 2005-11-01 |
| Vaccine Treatment for Surgically Resected Pancreatic Cancer (NCT00255827) | NewLink Genetics Corporation | 2005-11-01 |
| Depression, Cytokines and Pancreatic Cancer (NCT00582699) | Memorial Sloan Kettering Cancer Center | 2005-11-01 |
| Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors (NCT00622674) | Masonic Cancer Center, University of Minnesota | 2005-11-01 |
| Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer (NCT00260364) | Royal Marsden NHS Foundation Trust | 2005-11-01 |
| Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer (NCT00460174) | Northwestern University | 2005-10-10 |
| Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00303758) | Federation Francophone de Cancerologie Digestive | 2005-10-01 |
| Individualized Drug Treatment for Treating Patients With Pancreatic Cancer (NCT00276744) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2005-10-01 |
| Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer (NCT00310050) | Wake Forest University Health Sciences | 2005-10-01 |
| Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy (NCT00639314) | Wakayama Medical University | 2005-10-01 |
| PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca (NCT00467116) | Vanderbilt-Ingram Cancer Center | 2005-10-01 |
| Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer (NCT00547144) | George Albert Fisher | 2005-10-01 |
| Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer (NCT00128622) | H. Kim Lyerly | 2005-09-01 |
| Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment (NCT00288925) | Zeria Pharmaceutical | 2005-09-01 |
| Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients (NCT00338039) | M.D. Anderson Cancer Center | 2005-09-01 |
| Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer (NCT00161213) | University of Medicine and Dentistry of New Jersey | 2005-09-01 |
| MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00112580) | Bristol-Myers Squibb | 2005-07-31 |
| Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer (NCT00121745) | Epeius Biotechnologies | 2005-07-01 |
| A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer (NCT01214720) | Hoffmann-La Roche | 2005-07-01 |
| Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer (NCT00486460) | Tel-Aviv Sourasky Medical Center | 2005-06-01 |
| Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss (NCT00899158) | Case Comprehensive Cancer Center | 2005-06-01 |
| Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer (NCT00112528) | Alliance for Clinical Trials in Oncology | 2005-06-01 |
| Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer (NCT00966706) | IRCCS San Raffaele | 2005-06-01 |
| Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00376948) | Barbara Ann Karmanos Cancer Institute | 2005-05-01 |